Stable formulations for parenteral injection of peptide drugs
Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided. In particular, the present invention provides stable formulations for parenteral injection of glucagon and methods of using such glucagon formulations to treat hypoglycemia, especially severe hypoglycemia in emergency situations.
1. A stable solution for parenteral injection, comprising:
a pramlintide peptide or a salt thereof, wherein the pramlintide peptide has been dried in a non-volatile buffer selected from glycine buffers, citrate buffers, phosphate buffers, and mixtures thereof, and wherein the dried pramlintide peptide has a pH memory of from about 3.0 to about 6.0 that is about equal to the pH of the pramlintide peptide in the non-volatile buffer, solubilized in an aprotic polar solvent selected from dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP), ethyl acetate, or a mixture thereof;
wherein the moisture content of the formulation is less than 5% w/w, and wherein the dried pramlintide peptide maintains the pH memory that is about equal to the pH of the peptide in the non-volatile buffer when the dried pramlintide peptide is solubilized in the aprotic polar solvent.
2. The formulation in accordance with claim 1 , wherein the non-volatile buffer is glycine buffer.
3. The formulation in accordance with claim 1 , wherein the non-volatile buffer is citrate buffer and the pH memory is about 4.0.
4. The formulation in accordance with claim 1 , wherein the aprotic polar solvent is DMSO.
5. The formulation in accordance with claim 1 , wherein the aprotic polar solvent is a mixture of DMSO and NMP.
6. The formulation in accordance with claim 1 , wherein the aprotic polar solvent is a mixture of DMSO and ethyl acetate.
7. The formulation in accordance with claim 1 , further comprising a co-solvent that depresses the freezing point of the formulation, wherein the co-solvent is selected from ethanol, propylene glycol, glycerol, and mixtures thereof.
8. The formulation in accordance with claim 7 , wherein the co-solvent is ethanol or propylene glycol.
9. The formulation in accordance with claim 7 , wherein the co-solvent is present in the formulation in an amount ranging from about 10% w/v to about 50% w/v.
10. The formulation in accordance with claim 1 , further comprising a stabilizing excipient.
11. The formulation in accordance with claim 10 , wherein the stabilizing excipient is selected from sugars, starches, and mixtures thereof.
12. The formulation in accordance with claim 11 , wherein the stabilizing excipient is a sugar.
13. The formulation in accordance with claim 12 , wherein the sugar is trehalose.
14. The formulation in accordance with claim 11 , wherein the stabilizing excipient is a starch.
15. The formulation in accordance with claim 14 , wherein the starch is hydroxyethyl starch (HES).
16. A stable solution for parenteral injection, comprising:
a pramlintide peptide or a salt thereof, wherein the pramlintide peptide has been dried in a non-volatile buffer, and wherein the dried pramlintide peptide has a pH memory of from about 3.0 to about 6.0 that is about equal to the pH of the pramlintide peptide in the non-volatile buffer, solubilized in an aprotic polar solvent selected from dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP), ethyl acetate, or a mixture thereof;
wherein the moisture content of the formulation is less than 5% w/w, and wherein the dried pramlintide peptide maintains the pH memory of from about 3.0 to about 6.0 that is about equal to the pH of the pramlintide peptide in the non-volatile buffer when the dried pramlintide peptide is solubilized in the aprotic polar solvent.